UPDATE: Deutsche Bank Starts ABIOMED (ABMD) at Buy, 'Size Matters'

June 18, 2021 6:04 AM EDT
Get Alerts ABMD Hot Sheet
Price: $324.81 +0.31%

Rating Summary:
    11 Buy, 6 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 11 | New: 19
Trade Now! 
Join SI Premium – FREE
(Updated - June 18, 2021 6:44 AM EDT)

Deutsche Bank analyst Pito Chickering initiates coverage on ABIOMED (NASDAQ: ABMD) with a Buy rating and a price target of $360.00.

The analyst comments "ABMD is one of the most controversial names within our Medtech coverage universe. Over the past decade, there have been multiple debates on how useful the Impella pump is versus a standard balloon pump; then the debate shifted to reimbursement concerns and CMS potentially cutting payment rates; and then recently, it has shifted back to questions around Impella’s effectiveness. Despite these concerns on Wall Street, company revenues have grown from $100m in 2011 to $847m in 2021, which we believe shows the underlying demand from physicians and clinical merits of the technology."

For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.

Shares of ABIOMED closed at $312.61 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Deutsche Bank